RPL17 and non-small cell lung carcinoma: These clusters had various biological characteristics and treatment reaction: the ORR of immunotherapy for NSCLC due to KRAS mutations alone, KRAS co-mutations with STK11/LKB1 and TP53 was approximately 28.6%, 7.4% (because the blocking of PD-1 by immunosuppressive agents was reduced), and 35.7% (showing better efficacy), respectively (27).